A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Clinical trial NCT05878717 · RECRUITING

Trial details

NCT number: NCT05878717
Sponsor: GlaxoSmithKline
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Systemic Sclerosis Associated Interstitial Lung Disease Scleroderma, Systemic

Start date: 2023-09-13
Primary completion: 2029-05-17
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.